Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.78 |
| ▸ | S1PR3 | Q99500 | 12/20 | 0.66 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.66 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.66 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13851946 | 1.00 | S1PR1 (0.78) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL13851944 | 1.00 | S1PR1 (0.78) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL13463831 | 1.00 | S1PR1 (0.78) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL13851934 | 1.00 | S1PR1 (0.78) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL13851933 | 1.00 | S1PR1 (0.78) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL13851931 | 1.00 | S1PR1 (0.78) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL2465552 | 0.94 | S1PR1 (0.71) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL2464654 | 0.92 | S1PR1 (0.67) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL13664833 | 0.91 | S1PR1 (0.67) | S1PR1S1PR3S1PR4S1PR5S1PR2 | |
| SCHEMBL13665143 | 0.91 | S1PR1 (0.67) | S1PR1S1PR3S1PR4S1PR5S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637819-A1 | METHODS OF TREATING INFLAMMATORY DISEASES WITH COMBINATION OF TL1A INHIBITORS AND S1PR INHIBITORS | Prometheus Biosciences, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240299318-A1 | AMISELIMOD FOR PREVENTING, TREATING OR AMELIORATING ULCERATIVE COLITIS | JPMORGAN CHASE BANK, N.A. | 2024-09-12 | — | — | US | disclosed |
| WO-2024137353-A1 | METHODS OF TREATING INFLAMMATORY DISEASES WITH COMBINATION OF TL1A INHIBITORS AND S1PR INHIBITORS | PROMETHEUS BIOSCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-4288041-A1 | AMISELIMOD FOR PREVENTING, TREATING, OR AMELIORATING ULCERATIVE COLITIS | Bausch Health Ireland Limited (IE) | 2023-12-13 | — | — | EP | disclosed |
| CN-116940350-A | A Mi Mode for preventing, treating or ameliorating ulcerative colitis | 博施健康爱尔兰有限公司 | 2023-10-24 | — | — | CN | disclosed |
| WO-2022167690-A1 | AMISELIMOD FOR PREVENTING, TREATING, OR AMELIORATING ULCERATIVE COLITIS | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299318-A1 | AMISELIMOD FOR PREVENTING, TREATING OR AMELIORATING ULCERATIVE COLITIS | UNG, SI, TPMT | S1PR1 2612/4885S1PR3 2742/4885S1PR4 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.